We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Phoenix Group Holdings Plc | LSE:PHNX | London | Ordinary Share | GB00BGXQNP29 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.40 | 0.71% | 479.40 | 479.00 | 479.40 | 485.60 | 478.40 | 481.00 | 6,977,543 | 16:35:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Life Insurance | 22.81B | -116M | -0.1159 | -41.35 | 4.8B |
Date | Subject | Author | Discuss |
---|---|---|---|
10/1/2017 07:51 | It was a bit higher, yes, but they are a cautious lot and didn't ram home the point. However, as quoted in my post #2054, they have stated the cash sum they will pay out for H2 2016 and the whole of 2017. Note, too, that they are reorganising their debt by raising stuff on the bond market to repay bank loans. I don't think potential investors will be too keen to see an equity dividend hike. | jonwig | |
10/1/2017 07:44 | To my lay-, or lazy, eye the update says cash generation has been higher and faster than previously forecast. Am I right and, if so, does that imply there could be a higher dividend payout? (I took up some rights but not all; and now thinking to re-allocate as my largest holding in this sector is CSN). | sogoesit | |
09/1/2017 01:26 | Thank you for all the feedback. PHNX does look to be near the top now. Just considering LGEN as I like the look of what they are doing per the last annual report. If the derivatives concerns hit the fan though I would think both would suffer badly (knock-on effect of anything financial related) while GSK would weather the storm better. That is my main concern now. | lauders | |
08/1/2017 09:57 | Like GSK(largest single holding) however FCF will barely cover the dividend in 2017. Last year a significant part of their dividend was paid from debt. A rebasing of the GSK payout under a new CEO may happen as part of an invest for growth strategy, just my take. Added a few PHNX on Friday afternoon. | essentialinvestor | |
08/1/2017 08:57 | Lauders,I own shares in GSK,LGEN,and PHNX.If I had to choose between the 3,now it would be PHNX,for growth and a dividend income of at least 6%.Regarding HSD,there could be a possibility of a dividend cut.So play safe with PHNX.IMHO DYOR. | garycook | |
08/1/2017 08:24 | We had a long discussion of the forthcoming dividends back in October, but it does no harm to review it, as the Midas article has (probably) got it wrong ... Regarding the "54.7p dividend for 2016, rising to 57p for 2017", these numbers are stated in the RI prospectus, with the caveat that they are 'before adjustment for the rights issue'. The prospectus says clearly [p 56]: The incremental cashflow generation from the Acquisition supports (subject to regulatory approval) a proposed increase in dividends in respect of 2017 to £197 million. This is 50.14p/sh on the current 392.85m shares in issue. Also, they say "the Board is expecting to increase the final dividend in respect of 2016 to £69 million" which would be 17.6p, giving a total for 2016 of 44.3p. | jonwig | |
08/1/2017 07:31 | Thank you very much for that information jonwig. More interested now. A toss-up between GSK, LGN and PHNX now probably. Will see how much stronger PHNX get on the back of that Midas verdict. Might have to wait a bit for a dip & then act. I don't think the DOW, FTSE etc.. are going to continue going up and some sort of correction is due. As usual I will probably completely wrong! | lauders | |
08/1/2017 07:24 | Lauders, the important stuff is here at the end of the article: To minimise the chance of policyholders being left out of pocket, regulators make sure that life companies are exceptionally strong financially, so they are obliged to set aside significantly more capital than they are likely to need. As policies lapse or policyholders pass away, Phoenix is allowed to bring some of the surplus capital back into its business and each year a proportion of that money goes towards shareholder dividends. For City brokers, this is one of the most important ways to measure Phoenix, as it highlights the company’s financial stability and its likely future dividend payments. After the Abbey transaction, which was completed on December 30, Phoenix said it expected to generate at least £2.7billion of cash between now and 2020, which should translate into rising dividends over the coming years. Full-year results for 2016 will be released in March and analysts forecast a dividend of 54.7p, rising to 56p for the current year and equating to a dividend yield of more than 7 per cent. Bannister is actively looking for new deals and there is every chance that they will come his way. Many insurers and banks with life and pension divisions are keen to sell off their closed-life subsidiaries and focus on their core business instead. The overall UK closed-life market is valued at about £250billion and, as the leading player in the sector, Phoenix is well placed to buy any unwanted businesses. The company is disciplined in its approach to acquisitions, however, only buying firms that strengthen its financial position and enhance its ability to pay dividends. Midas verdict: Phoenix Group offers investors the prospect of healthy dividends over the long term and the shares should rise in price too. At 748½p, they are a buy. | jonwig | |
08/1/2017 02:05 | I cannot access that DM link as blocked in the the Far East where I live. Anything of great value anyone is willing to share from it please? GARYCOOK - Do you think the HSD dividend is sustainable? PHNX looks the safer of the two. I am looking for a good high yielder to just buy and forget and so far my choices are GSK, AZN, RDSB, CLLN, CNA, PHNX or HSD. I need it for QROPS pension related wrapper purposes so hence the buy and forget. Edit - Added LGEN to the list! | lauders | |
08/1/2017 00:07 | Agree.Big core holding for me,along with HSD for the dividend income. | garycook | |
07/1/2017 22:46 | Nice write up underlining the yield attractions. | essentialinvestor | |
07/1/2017 22:23 | Daily Mail tip | pillion | |
04/1/2017 14:01 | RCTurner21 Dec '16 - 07:32 - 2008 of 2046 0 0 Edit Anything under 750p is a bargain in my opinion. | rcturner2 | |
04/1/2017 13:49 | Have PHNX as a further add if we do get some sort of market pullback. | essentialinvestor | |
03/1/2017 16:12 | M&A in insurance: Life insurance operations, especially books that are closed to new business, are also likely to change hands. This year Aegon sold £9bn of UK annuities to Rothesay Lifeand Legal & General, while Phoenix, which specialises in closed books, made a series of acquisitions. That could continue as big insurers look to release capital from legacy businesses. Jean-Francois Izac, managing director at Lazard, says: “With continued pressure on capital and return, more back-book transactions are likely to take place over the next few years, potentially creating just a handful of large closed-book businesses in Europe in five to 10 years.” George Swan, an insurance partner at law firm Freshfields, agrees: “People are expecting quite a lot to happen in the annuity space as life insurers continue to seek to offload both closed and open books of business.” But it's uncertain when PHNX can act again. Apart from digestion, another fundraising looks out of the question for at least a year. | jonwig | |
03/1/2017 13:31 | Did not even realise I could check e-mails on my mob until about 2 years ago, luddite, or other words less polite ). | essentialinvestor | |
03/1/2017 13:27 | Ptolemy - nor was I being over-sceptical - I describe something as magic when it's beyond me, much as a primitive savage might a gun, let alone a smartphone. A purist in TA probably doesn't even look at newsflow, and so won't know or care what caused the adjustment. And yet chartists surely use their skills to make trading decisions. Isn't a sudden large price fall a signal to act? It messes up trendlines, support levels, etc. | jonwig | |
03/1/2017 13:11 | Just to be clear, I'm not sure what is my view! I posted because the pattern is unusual. Has it completed? I don't know. According to Lindsay it should go lower. But the June low was a .618 fibo, which would be a good bounce zone if sentiment has changed. And, soon, a very clean IHS will come into play. It's not unreasonable for a pattern to terminate short of a 'textbook finish' if a strong push is coming. I like the fundamentals and will jump in if the TA merits a punt. I remain open minded. | ptolemy | |
03/1/2017 12:20 | Ptolemy is usually sharper than an unsed scalpel, so I take notice of his views. | essentialinvestor | |
03/1/2017 11:49 | J, TA is based on price and, to state the obvious, the price is the price. Irrespective of whether or not a price change is due to issuing shares, a dividend payment, news flow or something else. | ptolemy | |
03/1/2017 10:53 | Ptolemy - is your magick adjusted for the 7:12 rights issue? | jonwig | |
03/1/2017 10:45 | The near 300K connected person buy is hopefully a positive sign. | essentialinvestor | |
03/1/2017 10:25 | PHNX Currently showing one of the clearest examples of George Lindsay’s uncommon technical pattern, “3 Peaks and a Domed House.” Question is are moves 26-28 complete? | ptolemy | |
29/12/2016 09:10 | Added a few this AM. Really wish I had topped up CSN a couple of weeks ago, hesitated. | essentialinvestor | |
29/12/2016 07:39 | Henry Staunton (PHNX Chair) used to be on the board of LGEN until 2013. A noted City grandee. | jonwig |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions